The global breast biopsy devices market is set to experience significant growth, with a projected compound annual growth rate (CAGR) of 5.5% from 2022 to 2032. The market, valued at approximately USD 2.1 billion in 2022, is expected to reach around USD 3.6 billion by the end of the forecast period. This growth is driven by the increasing prevalence of breast cancer, along with advancements in biopsy technology that enable more accurate and minimally invasive procedures.
The biopsy needle segment holds a substantial share of the market, contributing around 23.4% of the global market share as of 2021. Biopsy needles are crucial in providing accurate tissue samples for diagnosis and play a vital role in the early detection of breast cancer. The growing emphasis on early cancer detection and the increasing number of breast cancer screenings globally are major factors contributing to the demand for biopsy devices.
Innovations in breast biopsy techniques, such as automated needle systems and image-guided biopsy technologies, are further improving the precision and patient comfort, which are expected to fuel the market’s expansion. Additionally, the rise in awareness regarding breast cancer prevention and diagnosis is expected to drive adoption, particularly in emerging markets where healthcare infrastructure is improving.
Grab Your Complete Report Instantly – https://www.futuremarketinsights.com/reports/breast-biopsy-device-market
Key Takeaways:
- The breast biopsy devices market is expected to grow at a 5.5% CAGR, reaching $3.6 billion by 2032.
- The biopsy needle segment holds a significant share, contributing 23.4% of the market in 2021.
- Technological advancements and the increasing focus on early cancer detection are key drivers of growth.
- The rising global prevalence of breast cancer and enhanced screening initiatives are expected to further propel market demand.
Market Drivers
- Increasing Incidence of Breast Cancer: The rising number of breast cancer cases globally is a primary driver for the demand for breast biopsy devices, as these tools are essential for diagnosis and treatment planning.
- Growing Awareness and Screening Programs: Enhanced awareness about breast health and the importance of early detection has led to increased screening initiatives, resulting in higher usage of biopsy devices.
- Technological Advancements: Innovations in biopsy techniques and devices, such as minimally invasive procedures and improved imaging technologies, are making biopsies safer and more effective, thus driving market growth.
- Funding for Cancer Research: Increased funding and investment in cancer research are contributing to advancements in diagnostic technologies, including breast biopsy devices.
- Aging Population: An aging demographic that is more susceptible to breast cancer is further fueling the demand for these medical devices.
Challenges
- Regulatory Hurdles: Obtaining regulatory approvals for new biopsy devices can be a lengthy and complex process, potentially delaying product launches.
- High Costs of Devices: The cost associated with advanced biopsy devices may limit their accessibility in certain healthcare settings.
Competitive Landscape
Key players are focused on the development and launch of novel detection devices for breast cancers. Established players within the industry are targeting specific female groups and going after strategic mergers and acquisitions to strengthen their position in the breast biopsy devices market.
- For instance, in Mar 2022, Hologic, Inc., an innovative medical technology company primarily focused on improving women’s health, opened its Innovation Center today in Aix-en-Provence, France. The new commercial office and training and research and development facility will support Hologic’s ultrasound, interventional, and surgical solutions across the continuum of breast health care.
- In April 2021, Unilabs and GE Healthcare signed a partnership agreement. GE Healthcare provides technically advanced MRIs and CT scanning technology, ultrasound devices, mammography, and X-ray machines to Unilabs in Portugal.
Similarly, recent developments related to companies manufacturing breast biopsy device techniques have been tracked by the team at Future Market Insights, which are available in the full report.
Key Companies Profiled
- ARGON MEDICAL
- Becton Dickinson and Company
- C.R. Bard, Inc.
- Cook Medical Inc.
- Devicor Medical Products, Inc.
- F. Hoffmann-La Roche Ltd.,
- GE Healthcare
- Hologic, Inc.
- Leica Biosystems
- Medax Srl Unipersonale
- Planmed Oy,
- Scion Medical Technologies, LLC
- Siemens Healthier
Key Market Segments Covered in Breast biopsy Devices Industry Research
By Product:
- Biopsy Needle
- Core Needles
- Fine Aspiration Needles
- MRI-Guide Biopsy Systems
- Ultrasound Guided Breast Biopsy Systems
- Two-Dimensional (2-D) Mammographic Ultrasonic Scanning Systems
- Three-Dimensional (3-D) B-Mode Mammographic Ultrasonic Scanning Systems
- Vacuum-Assisted Device (VAD)
- Guide Wire (Localization Wire)
- Breast Biopsy Marker
By Indication:
- Complex cyst
- Solid mass
- Suspicious solid mass( fibroadenoma )
- Suspicious micro-calcifications
By End User:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Cancer Research Institutes
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa (MEA)
Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:
PD1 Resistant Head and Neck Cancer Market
Cystic Fibrosis Therapeutics Market
Barlow’s Syndrome Market
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube